Highest-materiality recent filing
Beyond Air receives Nasdaq delisting notice for bid price non-compliance; hearing requested
Nasdaq Staff notified Beyond Air that its common stock failed to maintain minimum $1.00 bid price per Listing Rule 5550(a)(2).
Nasdaq notified Beyond Air on Apr 7, 2026 that it fails Bid Price Rule; stock closed below $1 for 30 consecutive business days through Apr 6.
Beyond Air CEO Steve Lisi resigns; Robert Goodman appointed CEO effective March 27, 2026
Steve Lisi resigned as CEO and director, effective March 27, 2026; no disagreement with the Company.
Beyond Air Q3 revenue up 105% to $2.2M, net loss narrows; FY2026 guidance reaffirmed at $8-10M
Revenue $2.2M, up 105% YoY; gross profit $0.3M vs ($0.2M) gross loss prior year.
Beyond Air stockholders elect directors, ratify auditor, approve equity plan at 2026 annual meeting
All six director nominees elected: Steven A. Lisi, Robert S. Goodman, Robert F. Carey, Dr. William Forbes, Yoori Lee, Erick J. Lucera.
Beyond Air raises $5M in private placement of stock and warrants at $1.272/unit
Gross proceeds of $5.0M from sale of 3,930,818 shares (or pre-funded warrants) and five-year warrants at $1.147 strike.
XTL to acquire 85% of Beyond Air's NeuroNOS for equity, $1M cash, up to $32.5M milestones
XTL acquires 85% of NeuroNOS for 19.9% of XTL's share capital, $1M cash, and up to $32.5M in milestone payments.
Beyond Air appoints Dan Moorhead as CFO effective Jan 5, 2026; replaces interim CFO Duke Dewrell
Salary set at $325k; eligible for discretionary bonus and equity participation.
Beyond Air appoints Denton Dewrell as principal financial officer and principal accounting officer
Denton Dewrell, age 39, appointed as principal financial officer and accounting officer effective Dec 8, 2025.
CFO Doug Larson resigns; interim CFO Duke Drewell appointed
Doug Larson resigns as CFO effective Dec 5, 2025 to pursue another opportunity; no disagreement with company.
Beyond Air Q2 revenue up 128% to $1.8M; net loss narrows; secures $32M financing
Revenue $1.8M (+128% YoY); net loss ($7.9M) ($1.25/share) vs. ($13.4M) ($5.67/share).
Beyond Air secures up to $32M in financing from Streeterville Capital
Issued $12M promissory note with 15% annual interest; net proceeds ~$12M; $6M placed in restricted account.
Beyond Air receives ~$3.25M from warrant exercise; issues new warrants for 719,561 shares
Gross proceeds ~$3.25M from immediate exercise of 1,439,126 existing warrants at reduced price of $2.21/share.
NeuroNOS (Beyond Air unit) receives FDA Orphan Drug Designation for BA-101 in glioblastoma
FDA grants Orphan Drug Designation for BA-101, an investigational nNOS inhibitor, for treatment of glioblastoma.
Beyond Air Q1 revenue rises 157% to $1.8M; net loss narrows to $7.7M
Revenue $1.8M vs $0.7M YoY (+157%); gross profit $0.2M vs loss of $0.3M.
Beyond Air announces 1-for-20 reverse stock split to regain Nasdaq compliance
Reverse stock split ratio 1-for-20, effective July 14, 2025.
Beyond Air shareholders approve reverse stock split at up to 1-for-50 ratio
Shareholders approved reverse stock split ratio between 1-for-10 and 1-for-50, as determined by the Board.
Beyond Air Q4/FY2025 revenue $3.7M (+220% YoY); guides FY2026 $12-16M; filed PMA for LungFit PH II
Revenue $3.7M for FY2025, up 220% YoY; net loss $46.6M ($0.69 per share).
On June 16, 2025, the Board of Directors (the “Board”) of the Company appointed Robert Goodman as a member of the Board.
Max materiality 0.80 · Median 0.65 · Most common event other_material